Off-the-Shelf CAR-T cells take on tough leukemia
Disease control
Not yet recruiting
This early-stage study tests a new type of immunotherapy called universal CLL1 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses donor immune cells engineered to target and kill leukemia cells, ai…
Phase: PHASE1 • Sponsor: Mingfeng Zhao • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC